Real-World Associations of KidneyIntelX Risk Stratification With Guideline-Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease.

David Lam¹, Barry I Freedman², Joji Tokita³, Fergus Fleming⁴, Mayte Suarez-Farinas¹, Benjamin Bagwell², Julienne Kirk², Hazel Tapp², Lindsay Shade², Aida Vega¹, Stephanie Wang¹, Catherine Sinfield¹, Steven G Coca^3,4, Girish N Nadkarni^3,4, Michael J Donovan⁴

¹Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

²Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

³Barbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁴Renalytix AI, PLC, New York, New York, USA.

PubMed DOI

Abstract

BACKGROUND: KidneyIntelX is a prognostic blood test for the progression of diabetic kidney disease (DKD) within 5 years. Long-term utility is important. MATERIALS AND METHODS: Adults with type 2 diabetes (T2D) and CKD (G1-G3b) from two medical centres were assessed for the following: (1) baseline KidneyIntelX risk levels and their association with GDMT usage; (2) changes in temporal kidney and me…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.